Treatment of Abnormalities of Potassium Homeostasis in CKD

Biff F. Palmer, Deborah J. Clegg

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Hyperkalemia, defined as serum potassium concentrations greater than 5.0 to 5.5 mEq/L, is a frequent occurrence in clinical practice because of the increasing incidence and prevalence of CKD. Patients at risk for this disorder are commonly treated with drugs that interfere in the renin-angiotensin-aldosterone system, thereby enhancing the occurrence and prevalence of this disorder. Discontinuation of these drugs because of the development of hyperkalemia deprives these patients the renal-protective and cardiovascular benefits this class of pharmacology has been shown to provide. Here we provide the clinician strategies to both prevent and treat hyperkalemia in patients with CKD who are prescribed these drugs. We emphasize the importance of limiting dietary potassium intake and avoiding either prescribed or over-the-counter medications that may impair renal potassium excretion. We discuss the role of kaliuretic diuretics and correction of metabolic acidosis as a therapeutic strategy. Additionally, we discuss the role of new agents designed to bind potassium in the gastrointestinal tract that can be used to maintain normokalemia in patients who previously developed hyperkalemia on renin-angiotensin-aldosterone blockers. Finally, we provide a brief discussion on how best to treat hypokalemia in patients with CKD.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalAdvances in Chronic Kidney Disease
Volume24
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Hyperkalemia
Potassium
Homeostasis
Dietary Potassium
Pharmaceutical Preparations
Therapeutics
Hypokalemia
Angiotensins
Renin-Angiotensin System
Acidosis
Aldosterone
Diuretics
Renin
Gastrointestinal Tract
Pharmacology
Kidney
Incidence
Serum

Keywords

  • Hyperkalemia
  • Potassium
  • Renin-angiotensin-aldosterone inhibitors

ASJC Scopus subject areas

  • Nephrology

Cite this

Treatment of Abnormalities of Potassium Homeostasis in CKD. / Palmer, Biff F.; Clegg, Deborah J.

In: Advances in Chronic Kidney Disease, Vol. 24, No. 5, 01.09.2017, p. 319-324.

Research output: Contribution to journalReview article

@article{40189aadcda547c78a282a9bfcd54646,
title = "Treatment of Abnormalities of Potassium Homeostasis in CKD",
abstract = "Hyperkalemia, defined as serum potassium concentrations greater than 5.0 to 5.5 mEq/L, is a frequent occurrence in clinical practice because of the increasing incidence and prevalence of CKD. Patients at risk for this disorder are commonly treated with drugs that interfere in the renin-angiotensin-aldosterone system, thereby enhancing the occurrence and prevalence of this disorder. Discontinuation of these drugs because of the development of hyperkalemia deprives these patients the renal-protective and cardiovascular benefits this class of pharmacology has been shown to provide. Here we provide the clinician strategies to both prevent and treat hyperkalemia in patients with CKD who are prescribed these drugs. We emphasize the importance of limiting dietary potassium intake and avoiding either prescribed or over-the-counter medications that may impair renal potassium excretion. We discuss the role of kaliuretic diuretics and correction of metabolic acidosis as a therapeutic strategy. Additionally, we discuss the role of new agents designed to bind potassium in the gastrointestinal tract that can be used to maintain normokalemia in patients who previously developed hyperkalemia on renin-angiotensin-aldosterone blockers. Finally, we provide a brief discussion on how best to treat hypokalemia in patients with CKD.",
keywords = "Hyperkalemia, Potassium, Renin-angiotensin-aldosterone inhibitors",
author = "Palmer, {Biff F.} and Clegg, {Deborah J.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1053/j.ackd.2017.06.001",
language = "English (US)",
volume = "24",
pages = "319--324",
journal = "Advances in Chronic Kidney Disease",
issn = "1548-5595",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Treatment of Abnormalities of Potassium Homeostasis in CKD

AU - Palmer, Biff F.

AU - Clegg, Deborah J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Hyperkalemia, defined as serum potassium concentrations greater than 5.0 to 5.5 mEq/L, is a frequent occurrence in clinical practice because of the increasing incidence and prevalence of CKD. Patients at risk for this disorder are commonly treated with drugs that interfere in the renin-angiotensin-aldosterone system, thereby enhancing the occurrence and prevalence of this disorder. Discontinuation of these drugs because of the development of hyperkalemia deprives these patients the renal-protective and cardiovascular benefits this class of pharmacology has been shown to provide. Here we provide the clinician strategies to both prevent and treat hyperkalemia in patients with CKD who are prescribed these drugs. We emphasize the importance of limiting dietary potassium intake and avoiding either prescribed or over-the-counter medications that may impair renal potassium excretion. We discuss the role of kaliuretic diuretics and correction of metabolic acidosis as a therapeutic strategy. Additionally, we discuss the role of new agents designed to bind potassium in the gastrointestinal tract that can be used to maintain normokalemia in patients who previously developed hyperkalemia on renin-angiotensin-aldosterone blockers. Finally, we provide a brief discussion on how best to treat hypokalemia in patients with CKD.

AB - Hyperkalemia, defined as serum potassium concentrations greater than 5.0 to 5.5 mEq/L, is a frequent occurrence in clinical practice because of the increasing incidence and prevalence of CKD. Patients at risk for this disorder are commonly treated with drugs that interfere in the renin-angiotensin-aldosterone system, thereby enhancing the occurrence and prevalence of this disorder. Discontinuation of these drugs because of the development of hyperkalemia deprives these patients the renal-protective and cardiovascular benefits this class of pharmacology has been shown to provide. Here we provide the clinician strategies to both prevent and treat hyperkalemia in patients with CKD who are prescribed these drugs. We emphasize the importance of limiting dietary potassium intake and avoiding either prescribed or over-the-counter medications that may impair renal potassium excretion. We discuss the role of kaliuretic diuretics and correction of metabolic acidosis as a therapeutic strategy. Additionally, we discuss the role of new agents designed to bind potassium in the gastrointestinal tract that can be used to maintain normokalemia in patients who previously developed hyperkalemia on renin-angiotensin-aldosterone blockers. Finally, we provide a brief discussion on how best to treat hypokalemia in patients with CKD.

KW - Hyperkalemia

KW - Potassium

KW - Renin-angiotensin-aldosterone inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85037054494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037054494&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2017.06.001

DO - 10.1053/j.ackd.2017.06.001

M3 - Review article

C2 - 29031359

AN - SCOPUS:85037054494

VL - 24

SP - 319

EP - 324

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

SN - 1548-5595

IS - 5

ER -